The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Nanoengineering materials to combat antimicrobial resistance. This project aims to understand how nanoengineered materials can be designed to kill bacteria and fungi without causing antimicrobial resistance. Resistance to antimicrobial drugs already leads to many thousands of deaths annually and costs society billions of dollars. Nanomaterials have unique abilities to attack microbes in multiple ways that could limit resistance. This project will engineer new antimicrobial nanomaterials tailored ....Nanoengineering materials to combat antimicrobial resistance. This project aims to understand how nanoengineered materials can be designed to kill bacteria and fungi without causing antimicrobial resistance. Resistance to antimicrobial drugs already leads to many thousands of deaths annually and costs society billions of dollars. Nanomaterials have unique abilities to attack microbes in multiple ways that could limit resistance. This project will engineer new antimicrobial nanomaterials tailored to selectively kill microbes with reduced likelihood of developing resistance by using synergies between inorganic nanoparticles and antimicrobial peptides. This technology could be used to prevent infections and biofilms on surfaces in a wide range of future applications, such as medical / veterinary devicesRead moreRead less
Orientated biointerfacing of cell-mimetic nanoparticles. The project aims to create next-generation cell-mimetic nanotechnology by providing in-depth understandings and precise control over cell membrane coating orientation of biomimetic nanoparticles. Our approach is to design and develop new synthetic and analytic strategies to construct and quantify orientated biointerfacing. This will generate new knowledge and patentable methodologies related to orientated biomimetic nanoparticles. Expected ....Orientated biointerfacing of cell-mimetic nanoparticles. The project aims to create next-generation cell-mimetic nanotechnology by providing in-depth understandings and precise control over cell membrane coating orientation of biomimetic nanoparticles. Our approach is to design and develop new synthetic and analytic strategies to construct and quantify orientated biointerfacing. This will generate new knowledge and patentable methodologies related to orientated biomimetic nanoparticles. Expected outcomes include significant contributions to Australia's scholarly outputs, enhanced national capacity in disruptive nanotechnology, new opportunities for national value-add material manufacturing, and long-term benefits to biomedical and veterinary industries through new materials and nanotechnologies.
Read moreRead less
Novel ways of regulating epithelial transport. This project is intended to discover novel intracellular mechanisms that regulate the rate of ion transport by the lung, the gut and the kidney. It will not only provide new insights into how the body controls a process that is critical to animal life, but also provide new targets for the development of pharmaceuticals.
Genetic selection of artificial polyketides. This project aims to harness the potential of synthetic biology to build cells that can make valuable new derivatives of polyketides. Polyketides are natural products that have proven to be highly effective for use in industry, medicine and agriculture. The technologies developed in this project will provide resources to discover new chemicals, accessible to almost any scientific laboratory. Expected outcomes include the opportunity to put the future ....Genetic selection of artificial polyketides. This project aims to harness the potential of synthetic biology to build cells that can make valuable new derivatives of polyketides. Polyketides are natural products that have proven to be highly effective for use in industry, medicine and agriculture. The technologies developed in this project will provide resources to discover new chemicals, accessible to almost any scientific laboratory. Expected outcomes include the opportunity to put the future of natural product discovery and optimisation in the hands of the wider scientific community, which will provide significant benefits, such as providing new tools for Australian industries.Read moreRead less
Neurotrophic Active Natural Products: Total Synthesis and Biological Evaluation of Neovibsanins A and B, and Analogues. New chemical entities (drug candidates) that promote neurite outgrowth have significant ramifications to mankind as they have real potential to repair damaged, or grow replacement, nerve cells affected by neuro and central nervous system (CNS) degenerative disease (e.g. Alzhiemer's, Parkinson's, Huntington's etc). This scientific endeavour will reveal new drug like molecules fo ....Neurotrophic Active Natural Products: Total Synthesis and Biological Evaluation of Neovibsanins A and B, and Analogues. New chemical entities (drug candidates) that promote neurite outgrowth have significant ramifications to mankind as they have real potential to repair damaged, or grow replacement, nerve cells affected by neuro and central nervous system (CNS) degenerative disease (e.g. Alzhiemer's, Parkinson's, Huntington's etc). This scientific endeavour will reveal new drug like molecules for potential biological and clinical application, thereby assisting a substantial proportion of Australians suffering from these debilitating diseases. Read moreRead less
DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the dr ....DNA interactions of polynuclear platinum. Mechanistic NMR studies probing the origin of the unique antitumour activity of BBR3464. BBR3464 is one of a class of structurally unique platinum anticancer drugs that is currently undergoing clinical trials. The anticancer activity most likely depends on binding to DNA, but the mechanism is quite different from that of the widely used drug, cisplatin. This project uses NMR spectroscopy to follow the processes involved in the initial binding of the drug to DNA and the subsequent reactions of the adducts formed. The results of this work will aid in the selection of back-up clinical candidates and in the design of drugs that target specific sequences of DNA for use in novel gene-based therapies.Read moreRead less
Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at t ....Probing polynuclear platinum biomolecule interactions. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration with the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
The Properties of Enteric Reflexes Recorded in Vivo. The benefit of the work will be a clear understanding of how a key body system, the digestive system is controlled. This will bring a new understanding of how intestinal function is influenced by the food that we eat and also by medicinal compounds. In the longer term, it may lead to development of dietary programs that improve digestive health and to ways to test for adverse or beneficial effects of drugs on the intestine.
Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration betwe ....Second Generation Polynuclear Platinum Compounds. Mechanistic NMR Studies Probing DNA Binding and Pharmacokinetics. Cancer affects one in four Australians and 50% of cancer patients are treated with cisplatin. BBR3464 is a new type of platinum anticancer drug that has shown promise in clinical trials, including results in cancers that do not respond to cisplatin treatment. Second-generation analogues, now under development, may offer significant advantages. This international collaboration between Prof. Berners-Price and the inventor of these new drugs puts Australian research at the forefront of the clinical development. There is the potential for the generation of new IP from new strategies in the design of improved anticancer drugs. The project builds strong international links and provides international training for Australian PhD students. Read moreRead less
Gold phosphine and carbene complexes as potential antimitochondrial anticancer agents: design, synthesis and biological chemistry. To overcome the two major problems associated with existing anticancer drugs (resistance to therapy and lack of discrimination between normal and cancer cells) there is much current interest in targeting mitochondrial cell death pathways in chemotherapy. This project will probe the mode of action of a series of gold complexes containing pyridylphosphines that may ac ....Gold phosphine and carbene complexes as potential antimitochondrial anticancer agents: design, synthesis and biological chemistry. To overcome the two major problems associated with existing anticancer drugs (resistance to therapy and lack of discrimination between normal and cancer cells) there is much current interest in targeting mitochondrial cell death pathways in chemotherapy. This project will probe the mode of action of a series of gold complexes containing pyridylphosphines that may act by an antimitochondrial mechanism. Also, we will evaluate a new family of gold complexes based on carbene rather than phosphine components. Such compounds offer the potential advantages of ease of synthesis, lower toxicity and the ability to fine-tune molecular properties to maximise anticancer activity.Read moreRead less